© 2021 MJH Life Sciences and Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways. All rights reserved.
© 2021 MJH Life Sciences™ , Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways. All rights reserved.
July 14, 2020
Ramez N. Eskander, MD, explains the rationale for treating a 71-year-old woman with ovarian cancer with the PARP inhibitor rucaparib upon relapse.
May 29, 2020
Ramez Eskander, MD, presents the case of a 68-year-old woman with stage IV ovarian cancer, and discusses the management approach for this patient and similar cases.
March 25, 2019
Ramez N. Eskander, MD, discusses the current outlook for the frontline treatment landscape in ovarian cancer.